News about "IQVIA"

Innogen Wins PIC/S GMP Certification for Efsubaglutide Alfa

Innogen Pharmaceuticals has secured PIC/S GMP certification, validating its manufacturing quality and supporting the global expansion of efsubaglutide alfa.

IQVIA | 04/08/2026 | By News Bureau

Glenmark Pharma USA Launches Generic Milnacipran Tablets

Glenmark Pharmaceuticals USA has launched Milnacipran Hydrochloride tablets in multiple strengths as the authorised generic of Savella, expanding treatment access in the US market.

IQVIA | 20/03/2026 | By News Bureau |  150

Iqvia and Duke Clinical Research Institute Partner to Advance Obesity and Cardiometabolic Clinical Trials

Iqvia and DCRI have formed a strategic collaboration to enhance the design and execution of obesity and cardiometabolic clinical trials, combining global operational capabilities with academic research expertise.

Iqvia | 12/02/2026 | By News Bureau |  252

IQVIA and Boehringer Ingelheim Partner on Global Commercial Data Transformation

The long-term strategic collaboration aims to modernise Boehringer Ingelheim’s global commercial data foundation, enabling scalable, advanced analytics across therapeutic areas and regions using IQVIA’s industry-leading data model.

IQVIA | 31/01/2026 | By News Bureau |  359

Glenmark Launches Epinephrine Injection Multi-Dose Vial

Glenmark has introduced its Epinephrine Injection USP, 1?mg/mL, 30?mg/30?mL multiple-dose vial, which is bioequivalent and therapeutically equivalent to the reference drug by BPI Labs, LLC (NDA 205029), offering a reliable alternative for patients and healthcare providers.

IQVIA | 23/12/2025 | By News Bureau |  201

Granules Pharma Gets US FDA Tentative Approval for Generic ADZENYS XR-ODT

Granules Pharmaceuticals Inc has received tentative approval from the US FDA for its generic version of Amphetamine Extended-Release Orally Disintegrating Tablets (ADZENYS XR-ODT), which will be manufactured at the company’s US-based facility in Chantilly, Virginia.

IQVIA | 22/12/2025 | By News Bureau |  216

Lupin Launches Liraglutide Injection in US

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.

IQVIA | 04/10/2025 | By Dineshwori |  275

Lupin Receives Approval from US FDA for Rivaroxaban for Oral Suspension

Lupin’s Rivaroxaban will be manufactured at the company’s Chhatrapati Sambhajinagar facility.

IQVIA | 01/10/2025 | By Dineshwori |  347

Lupin Receives Tentative Approval from US FDA for its HIV treatment tablets

Lupin has received tentative US FDA approval for Bictegravir, Emtricitabine and Tenofovir Alafenamide Tablets to treat HIV, bioequivalent to Gilead’s Biktarvy, for adults and paediatric patients over 25 kg.

IQVIA | 25/09/2025 | By Dineshwori |  243

NVIDIA Teams Up with Industry Leaders to Accelerate Genomics and Drug Discovery

Healthcare leaders IQVIA, Illumina and Mayo Clinic, as well as Arc Institute, are using the latest NVIDIA technologies to develop solutions that will help advance human health.

IQVIA | 15/01/2025 | By Aishwarya |  570